Schonfeld Strategic Advisors LLC Aquestive Therapeutics, Inc. Transaction History

Schonfeld Strategic Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.01 - $6.09 $126,121 - $382,129	62,747 New	62,747 $267,000
Q2 2023 Aug 14, 2023	BUY	$1.06 - $2.49 $17,914 - $42,081	16,900 New	16,900 $27,000
Q4 2022 Feb 14, 2023	BUY	$0.77 - $1.18 $76,923 - $117,882	99,900 Added 24.56%	506,600 $455,000
Q3 2022 Nov 14, 2022	BUY	$0.63 - $1.73 $205,128 - $563,288	325,600 Added 401.48%	406,700 $475,000
Q2 2022 Aug 15, 2022	SELL	$0.64 - $2.57 $12,096 - $48,573	-18,900 Reduced 18.9%	81,100 $52,000
Q1 2022 May 16, 2022	SELL	$2.28 - $4.26 $12,995 - $24,282	-5,700 Reduced 5.39%	100,000 $261,000
Q4 2021 Feb 14, 2022	BUY	$3.69 - $6.37 $390,033 - $673,309	105,700 New	105,700 $411,000
Q4 2018 Feb 14, 2019	SELL	$6.09 - $18.0 $68,159 - $201,456	-11,192 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$15.0 - $18.96 $167,880 - $212,200	11,192 New	11,192 $196,000

122

46.8M

517K

207K

Ticker AQST
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,350,700
Market Cap $243M
Description
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.